Genome Editing by CRISPR | NMI TT Pharmaservices

home contact company.overview news sitemap print

Custom Cell Services

Contact

NMI-TT Contact Person

Dr. Richard Griesbach

+49 7121 51530 74


Download Flyer


Genome Editing by CRISPR/Cas9

Based on our long-standing expertise in generating customised cell lines, we are now also employing the CRISPR/Cas9 genome editing approach. FTO is ensured through a set of license agreements.

    Our offerings:
  • Introduction of specifically site-directed double stand breaks applying the CRISPR/Cas9 technology
  • Generation of target-defective cell lines
  • Larger deletions by two double strand breaks
  • Insertion of specific mutations or extensions into the DNA locus with ectopic repair templates
  • Generation of synthetic human hiPSC disease models
The CRISPR/Cas9 technology can also be used for target validation, analogous to RNAi mediated target silencing.



 

Linked in profile

NMI TT is a subsidiary of NMI